Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimportation Survey Demonstrates Rx Industry’s Public Relations Challenge

Executive Summary

Pharmaceutical companies' opposition to importing drugs from Canada into the U.S. is "unreasonable," according to a survey of Americans released Oct. 9

You may also be interested in...



Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing

Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8

FDA Steps Up Campaign Against Rx Imports; Bill “Technically” Flawed

Pending federal legislation to allow importation of prescription drugs from Canada would create unworkable conflicts with state pharmacy laws, FDA Commissioner Mark McClellan told the National Association of Boards of Pharmacy legislative conference Sept. 14 in Washington, D.C

Medicare Rx “Plan B”: Rep. Burton Chairs First Public Discussion On Fallback

Alternatives to passing a full Medicare prescription drug benefit will be given their first public airing since the Medicare conference committee was formed when the House Government Reform/Human Rights & Wellness Subcommittee convenes for a hearing Sept. 24

Related Content

UsernamePublicRestriction

Register

PS042630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel